Adult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro
Eli Lilly reported stellar third-quarter earnings yesterday and raised this year's revenue estimates from $60 billion–$62 billion to $63 billion–$63.5 billion.
(Fortune, 2025-10-31T16:40:39Z)